<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136015</url>
  </required_header>
  <id_info>
    <org_study_id>TKIs-cml-001</org_study_id>
    <nct_id>NCT04136015</nct_id>
  </id_info>
  <brief_title>Early Conversion of Dasatinib in CML-CP Patients</brief_title>
  <official_title>A Prospective Study on Early Conversion of Dasatinib in CML-CP Patients Who Have Not Early Molecular Response on Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic myeloid leukemia (CML) is a malignant disease of acquired hematopoietic stem cells.&#xD;
      The BCR-ABL fusion gene is the pathogenic basis of CML. Tyrosine kinase inhibitors (TKIs) are&#xD;
      targeted drugs for this fusion protein. With the wide clinical application of TKIs, the&#xD;
      efficacy of CML patients has been greatly improved. However, there are still a significant&#xD;
      number of patients who have poor response to the first generation of TKI drugs, imatinib,&#xD;
      most of them have early molecular response failures (BCR-ABL（IS）&gt;10% at 3 or 6 months) ，which&#xD;
      means lower rates of molecular response, increased risk of progression, and higher overall&#xD;
      survival. For them, the early conversion of dasatinib might be a better choice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMR in 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>MMR(BCR/ABL(IS)&lt;0.1%) at 12 months after switching to dasatinib for patients who did not achieve optimal treatment with imatinib for 3 to 6 months.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Validity and Safety</condition>
  <arm_group>
    <arm_group_label>Dasatinib group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib 100 MG</intervention_name>
    <description>The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group</description>
    <arm_group_label>Dasatinib group</arm_group_label>
    <arm_group_label>Imatinib group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CML-CP patients treated with imatinib failed to achieve the best therapeutic&#xD;
        effect（BCR/ABLIS&gt;10.00% in 3m or BCR/ABLIS&gt;1.00% in 6m）convert to dasatinib.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.18-65 years old； 2.CML-CP,and Imatinib treatment longest for 6 months ； 3.Q-pcr&#xD;
        monitoring of BCR/ABLIS failed to achieve the best therapeutic effect（BCR/ABLIS&gt;10.00% in&#xD;
        3m or BCR/ABLIS&gt;1.00% in 6m）； 4.No previous history of malignant tumor; 5.Informed consent&#xD;
        of the patient or his legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of CML-CP or CML-AP;&#xD;
&#xD;
          2. Resistant to dasatinib,or treatment with imatinib more than 6 months;&#xD;
&#xD;
          3. Received allogeneic hematopoietic stem cell transplantation,or immunotherapy;&#xD;
&#xD;
          4. woman who is pregnant or nursing&#xD;
&#xD;
          5. Combined with other serious organic diseases, serious arrhythmia, pulmonary&#xD;
             hypertension, cardiomyopathy, serious autoimmune diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>NanfangH</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

